




版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、Source Mackay, J, Mensah, G. The Atlas of Heart Disease and Stroke.WHO-CDC, 2004.Total number of Deaths: 57 millionOnset6 months1 year0.000.020.040.060.080.100.120.1418 months2 yearsCumulativedistributionWHO PREMISE Study of secondary prevention of strokeCauses of stroke and its established risk fac
2、torsNon-modifiable and modifiable risk factorsResults of the WHO PREMISE Study Prevalence of the most important risk factorsUse of medication from the WHO PREMISE Study By socio-demographic characteristicsAccording to risk factorsBy clinical characteristicsPredictors for the use of medicationPerspec
3、tives of pharmacological interventionClinical trials with universal treatmentSpecific treatment according to diagnosis: isquemic/hemorrhaegic strokeComplianceWHO PREMISE Study of secondary prevention of strokeCauses of stroke and its established risk factorsNon-modifiable and modifiable risk factors
4、Results of the WHO PREMISE StudyPrevalence of the most important risk factorsUse of medication from the WHO PREMISE StudyBy socio-demographic characteristicsAccording to risk factorsBy clinical characteristicsPredictors for the use of medicationPerspectives of pharmacological interventionClinical tr
5、ials with universal treatmentSpecific treatment according to diagnosis: isquemic/hemorrhaegic strokeComplianceSource Mackay, J, Mensah, G. The Atlas of Heart Disease and Stroke.WHO-CDC, 2004.WHO PREMISE Study of secondary prevention of strokeCauses of stroke and its established risk factorsNon-modif
6、iable and modifiable risk factorsResults of the WHO-PREMISE StudyPrevalence of the most important risk factorsUse of medication from the WHO PREMISE StudyBy socio-demographic characteristicsAccording to risk factorsBy clinical characteristicsPredictors for the use of medicationPerspectives of pharma
7、cological interventionClinical trials with universal treatmentSpecific treatment according to diagnosis: isquemic / hemorrhaegic strokeCompliance010203040506070BREGINIDIRPKSLTK RUTNTOTALCountries%60 yearsAGE GROUPS FOR MALES AND FEMALES0102030405060CHD FemalesCHD MalesCeVD FemalesCeVD Males%60 years
8、TOTAL NUMBER OF PARTICIPANTS OF CHD AND STROKEBY AGE AND SEX CeVD: Cerebrovascular disease WHO-PREMISE STUDY0102030405060708090100BREGINIDIRPKSLTKRUTNTOTALCountries%H B PH B CH B SWHO-PREMISE STUDY010203040506070BREGINIDIRPKSLTKRUTNTOTALCountries%0 FR1 FR2 FR3 FR4 FRHolzgreve and Middeke, 1994WHO PR
9、EMISE Study of secondary prevention of strokeCauses of stroke and its established risk factorsNon-modifiable and modifiable risk factorsResults of the WHO-PREMISE StudyPrevalence of the most important risk factorsUse of medication in the WHO PREMISE StudyBy socio-demographic characteristicsAccording
10、 to risk factorsBy clinical characteristicsPredictors for the use of medicationPerspectives of pharmacological interventionClinical trials with universal treatmentSpecific treatment according to diagnosis: isquemic/hemorrhaegic strokeComplianceWHO-PREMISE STUDYHBP: High blood pressure HBC: High bloo
11、d cholesterol HBS: High blood sugar WHO-PREMISE STUDYWHO-PREMISE STUDYWHO PREMISE Study of secondary prevention of strokeCauses of stroke and its established risk factorsNon-modifiable and modifiable risk factorsResults of the WHO PREMISE Study Prevalence of the most important risk factorsUse of med
12、ication from the WHO PREMISE StudyBy socio-demographic characteristicsAccording to risk factorsBy clinical characteristicsPredictors for the use of medicationPerspectives of pharmacological interventionClinical trials with universal treatmentSpecific treatment according to diagnosis: isquemic/hemorr
13、haegic strokeCompliance Total stroke 307/3051 420/3054 Major vascular events Total events 458/3051 604/3054 Events/patients Active* PlaceboFavorsactiveFavorsplaceboRisk reduction(95%CI)Stroke 32% (17 to 44) 27% (8 to 42) 28% (17 to 38) 29% (16 to 40) 24% (9 to 37) 26% (16 to 34)0.52.0 Hazard ratio1.
14、0Reference: Progress Study.Lancet 2001; 358: 1033-41*Active: Perindopril 4 mg Indapamide 2,5 mgSource: EAFT (European Atrial Fibrillation Trial) Study GroupConsiderations of available information on the following items permit to outline high-priority research questions on the secondary prevention of
15、 stroke:Serum uric acid, diuretics and risk of ischaemic stroke in the Atherosclerosis Risk in Communities (ARIC) Study 13 413 individuals free of stroke or coronary artery disease 381 strokes occurred during the mean follow up of 12.6 years Subjects Uric acid quartiles at baseline (mg.dL-1) P for l
16、inear trend Up to 4.8 4.95.8 5.96.8 Above 6.9 No. of subjects 3243 2534 3183 2303 No. of events 51 45 85 86 Diuretic non- users Relative hazard 1.00 0.99 1.41 1.89 (Sig.) 0.01 No. of subjects 291 318 609 932 No. of events 16 14 29 55 Diuretic users Relative hazard 1.00 0.72 0.69 0.72 0.46 Hozawa A,
17、Folsom A, Ibrahim H, et al. Atherosclerosis, Epub Oct 2005 Serum uric acid, diuretic use and ischaemic stroke Oxidative stress appears to have a bearing on the occurrence of ischaemic stroke on stroke-related neurological damage Plasma uric acid has a dual purport Uric acid is a powerful endogenous
18、antioxidant 2-4 units of oxidants (superoxide anion radical and hydrogen peroxide) are formed per unit of uric acid produced through the action of xanthine oxidase Diuretics, even at low doses, reduce the renal excretion of uric acid The rise in plasma uric acid caused by diuretics and the attendant
19、 increase in total plasma antioxidant capacity blunt the increase in stroke risk possible due to excess uric acid and reactive species synthesis mediated by xanthine oxidase Reyes AJ. Cardiovasc Drugs Ther 2003;17:397414. Reyes AJ, Leary WP. J Hypertens 2003;21:17751777. Comparison of ximelagatran,
20、warfarin and placebo in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation Source Compared treatments Incidence (n) Odds Ratio (95% CI) Meta-analysis* Warfarin Placebo 32/1225 89/1236 W:P 0.346 (0.2290.522) (SPORTIF)* III and V trials Ximelagatran Warfarin 93/3665 91/3664 X:W 0.978 (0.7301-311) Imputed placebo analysis Ximelagat
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 生產(chǎn)車間新建標(biāo)準(zhǔn)廠房及配套附屬用房項(xiàng)目可行性報(bào)告
- 中國(guó)影視行業(yè)市場(chǎng)前景預(yù)測(cè)及投資價(jià)值評(píng)估分析報(bào)告
- 2025年中國(guó)研球機(jī)行業(yè)市場(chǎng)發(fā)展前景及發(fā)展趨勢(shì)與投資戰(zhàn)略研究報(bào)告
- 2025-2030年中國(guó)三指塑料把項(xiàng)目投資可行性研究分析報(bào)告
- 2024年全球及中國(guó)微粉顏料行業(yè)頭部企業(yè)市場(chǎng)占有率及排名調(diào)研報(bào)告
- 2025年中國(guó)藿香正氣水未來趨勢(shì)預(yù)測(cè)分析及投資規(guī)劃研究建議
- 2025年中國(guó)食品釀造機(jī)械行業(yè)市場(chǎng)全景調(diào)研及投資規(guī)劃建議報(bào)告
- 中國(guó)精細(xì)分離填料行業(yè)市場(chǎng)發(fā)展前景及發(fā)展趨勢(shì)與投資戰(zhàn)略研究報(bào)告(2024-2030)
- 2025年中國(guó)風(fēng)扇式電氣空間加熱器行業(yè)深度分析及發(fā)展前景預(yù)測(cè)報(bào)告
- 2018-2024年中國(guó)冰綠茶飲料市場(chǎng)運(yùn)行態(tài)勢(shì)及投資戰(zhàn)略咨詢研究報(bào)告
- 義務(wù)教育英語課程標(biāo)準(zhǔn)(2022年版)知識(shí)點(diǎn)匯總
- 普通貨物運(yùn)輸安全管理制度(全套)
- 義務(wù)教育英語課程標(biāo)準(zhǔn)(2022年版)知識(shí)點(diǎn)匯總
- 溢流壩模板工程專項(xiàng)方案
- 監(jiān)理旁站方案
- YY/T 1155-2019全自動(dòng)發(fā)光免疫分析儀
- GB/T 9855-2008化學(xué)試劑一水合檸檬酸(檸檬酸)
- GB/T 5211.5-2008顏料耐性測(cè)定法
- 第十九章.40年代詩歌
- GB/T 17362-2008黃金制品的掃描電鏡X射線能譜分析方法
- GA 1800.1-2021電力系統(tǒng)治安反恐防范要求第1部分:電網(wǎng)企業(yè)
評(píng)論
0/150
提交評(píng)論